{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:32:55Z","timestamp":1793413975928,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec id=\"ab-poi230069-4\"><jats:title>Importance<\/jats:title><jats:p>Bone mineral density (BMD) <jats:italic>z<\/jats:italic> scores in transgender adolescents decrease during puberty suppression with a gonadotropin-releasing hormone (GnRH) agonist. Previous research found that after short-term use of gender-affirming hormones (GAH), pretreatment <jats:italic>z<\/jats:italic> scores were not restored. Long-term follow-up studies are lacking.<\/jats:p><\/jats:sec><jats:sec id=\"ab-poi230069-5\"><jats:title>Objective<\/jats:title><jats:p>To assess BMD after long-term GAH treatment in transgender adults who used puberty suppression in adolescence.<\/jats:p><\/jats:sec><jats:sec id=\"ab-poi230069-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This single-center cohort study with follow-up duration of 15 years selected participants from a database containing all people visiting a gender identity clinic at an academic hospital in the Netherlands between 1972 and December 31, 2018. Recruitment occurred from March 1, 2020, to August 31, 2021. A total of 75 participants diagnosed with gender dysphoria who had used puberty suppression before age 18 years prior to receiving at least 9 years of long-term GAH were included.<\/jats:p><\/jats:sec><jats:sec id=\"ab-poi230069-7\"><jats:title>Exposures<\/jats:title><jats:p>Puberty suppression with a GnRH agonist followed by GAH treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-poi230069-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Lumbar spine, total hip, and femoral neck BMD and <jats:italic>z<\/jats:italic> scores before the start of puberty suppression, at start of GAH, and at short- and long-term follow-up.<\/jats:p><\/jats:sec><jats:sec id=\"ab-poi230069-9\"><jats:title>Results<\/jats:title><jats:p>Among 75 participants, 25 were assigned male at birth, and 50 were assigned female at birth. At long-term follow-up, the median (IQR) age was 28.2 (27.0-30.8) years in participants assigned male at birth and 28.2 (26.6-30.6) years in participants assigned female at birth. The median (IQR) duration of GAH treatment was 11.6 (10.1-14.7) years among those assigned male at birth and 11.9 (10.2-13.8) years among those assigned female at birth. The <jats:italic>z<\/jats:italic> scores decreased during puberty suppression. In individuals assigned male at birth, the mean (SD) <jats:italic>z<\/jats:italic> score after long-term GAH use was \u22121.34 (1.16; change from start of GnRH agonist: \u22120.87; 95% CI, \u22121.15 to \u22120.59) at the lumbar spine, \u22120.66 (0.75; change from start of GnRH agonist: \u22120.12; 95% CI, \u22120.31 to 0.07) at the total hip, and \u22120.54 (0.84; change from start of GnRH agonist: 0.01; 95% CI, \u22120.20 to 0.22) at the femoral neck. In individuals assigned female at birth, after long-term GAH use, the mean (SD) <jats:italic>z<\/jats:italic> score was 0.20 (1.05; change from start of GnRH agonist: 0.09; 95% CI, \u22120.09 to 0.27) at the lumbar spine, 0.07 (0.91; change from start of GnRH agonist: 0.10; 95% CI, \u22120.06 to 0.26) at the total hip, and \u22120.19 (0.94; change from start of GnRH agonist: \u22120.20; 95% CI, \u22120.26 to 0.06) at the femoral neck.<\/jats:p><\/jats:sec><jats:sec id=\"ab-poi230069-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study, after long-term use of GAH, <jats:italic>z<\/jats:italic> scores in individuals treated with puberty suppression caught up with pretreatment levels, except for the lumbar spine in participants assigned male at birth, which might have been due to low estradiol concentrations. These findings suggest that treatment with GnRH agonists followed by long-term GAH is safe with regard to bone health in transgender persons receiving testosterone, but bone health in transgender persons receiving estrogen requires extra attention and further study. Estrogen treatment should be optimized and lifestyle counseling provided to maximize bone development in individuals assigned male at birth.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2023.4588","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:33:32Z","timestamp":1698680012000},"page":"1332","source":"Crossref","is-referenced-by-count":51,"title":["Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones"],"prefix":"10.1001","volume":"177","author":[{"given":"Maria Anna Theodora Catharina","family":"van der Loos","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Amsterdam University Medical Center (UMC) at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Center of Expertise on Gender Dysphoria, Amsterdam UMC at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariska Caroline","family":"Vlot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital St Jansdal, Harderwijk\/Lelystad, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Tatting","family":"Klink","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine Elisabeth","family":"Hannema","sequence":"additional","affiliation":[{"name":"Center of Expertise on Gender Dysphoria, Amsterdam UMC at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pediatrics, Amsterdam UMC at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"den Heijer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Amsterdam University Medical Center (UMC) at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Center of Expertise on Gender Dysphoria, Amsterdam UMC at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal Maria","family":"Wiepjes","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Amsterdam University Medical Center (UMC) at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Center of Expertise on Gender Dysphoria, Amsterdam UMC at Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"poi230069r1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1210\/er.2014-1007","article-title":"Pubertal timing, bone acquisition, and risk of fracture throughout life.","volume":"35","author":"Bonjour","year":"2014","journal-title":"Endocr Rev"},{"key":"poi230069r2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jpeds.2016.09.056","article-title":"The determinants of peak bone mass.","volume":"180","author":"Gordon","year":"2017","journal-title":"J Pediatr"},{"issue":"5 Pt 1","key":"poi230069r3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/00006250-200205000-00008","article-title":"Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.","volume":"99","author":"Surrey","year":"2002","journal-title":"Obstet Gynecol"},{"key":"poi230069r4","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1530\/eje.0.151s047","article-title":"Bone development during GH and GnRH analog treatment.","volume":"151","author":"Antoniazzi","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"poi230069r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243894","article-title":"Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK.","volume":"16","author":"Carmichael","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"poi230069r6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1515\/jpem-2019-0046","article-title":"The effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria: findings from a large national cohort.","volume":"32","author":"Joseph","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"poi230069r7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-039339","article-title":"Pubertal suppression, bone mass, and body composition in youth with gender dysphoria.","volume":"148","author":"Navabi","year":"2021","journal-title":"Pediatrics"},{"issue":"12","key":"poi230069r8","doi-asserted-by":"publisher","first-page":"e4252","DOI":"10.1210\/clinem\/dgaa604","article-title":"Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones.","volume":"105","author":"Schagen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"poi230069r9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jsxm.2019.06.014","article-title":"Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria.","volume":"16","author":"Stoffers","year":"2019","journal-title":"J Sex Med"},{"key":"poi230069r10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2016.11.008","article-title":"Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.","volume":"95","author":"Vlot","year":"2017","journal-title":"Bone"},{"issue":"2","key":"poi230069r11","doi-asserted-by":"publisher","first-page":"E270","DOI":"10.1210\/jc.2014-2439","article-title":"Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria.","volume":"100","author":"Klink","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"poi230069r13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jsxm.2018.01.016","article-title":"The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): trends in prevalence, treatment, and regrets.","volume":"15","author":"Wiepjes","year":"2018","journal-title":"J Sex Med"},{"issue":"9","key":"poi230069r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007038","article-title":"Dual energy X-ray absorptiometry body composition reference values from NHANES.","volume":"4","author":"Kelly","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"poi230069r17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD Position Development Conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics.","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"issue":"3","key":"poi230069r18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1373\/clinchem.2011.176545","article-title":"Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration.","volume":"58","author":"Heijboer","year":"2012","journal-title":"Clin Chem"},{"key":"poi230069r19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2016.08.016","article-title":"Various calibration procedures result in optimal standardization of routinely used 25(OH)D ID-LC-MS\/MS methods.","volume":"462","author":"Dirks","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"3","key":"poi230069r20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/jbmr.v34.3","article-title":"Bone safety during the first ten years of gender-affirming hormonal treatment in transwomen and transmen.","volume":"34","author":"Wiepjes","year":"2019","journal-title":"J Bone Miner Res"},{"key":"poi230069r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115669","article-title":"Growth of cortical bone thickness and trabecular bone density in Japanese children.","volume":"141","author":"Ozaki","year":"2020","journal-title":"Bone"},{"issue":"9","key":"poi230069r22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jclinepi.2013.03.017","article-title":"Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis.","volume":"66","author":"Twisk","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"poi230069r14"},{"key":"poi230069r15"},{"key":"poi230069r12","unstructured":"Government of the Netherlands. Wet Medisch-Wetenschappelijk Onderzoek Met Mensen. Published online January 1, 2020. Accessed September 25, 2023. https:\/\/wetten.overheid.nl\/BWBR0009408\/2020-01-01"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2811155\/jamapediatrics_van_der_loos_2023_oi_230069_1700242610.94225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T16:01:42Z","timestamp":1701705702000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2811155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2023.4588","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}